-
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes.
This is Part 3 in our series on how drugs get approved to treat lung cancer.
IN THE SPOTLIGHT
-
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are... -
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming... -
Countdown to ILCSC24: Bringing the World’s Experts Right to Your Living Room
Read time: 3 minutes. One of LUNGevity’s two flagship survivorship events, the International Lung Cancer Survivorship Conference (ILCSC), is being held virtually September 20 – 21... -
New NCCN Guidelines for Patients
The National Comprehensive Cancer Network (NCCN) is an alliance of leading cancer centers across the United States working together to improve cancer care. NCCN develops evidence... -
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with... -
SCLC Virtual Meetup
SCLC patients/survivors - Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. Register in advance for this... -
Small Cell Lung Cancer 101
Join small cell lung cancer expert Lauren Byers, MD, as she covers the key things patients need to know about SCLC in 30 minutes. Dr. Byers is a professor in the Department of... -
Researcher Aims to Bring 360-Degree Care to Young Adults Living with Lung Cancer
Young adults (less than 50 years of age) are being diagnosed with lung cancer at increasing rates. They tend to be women of Hispanic or Asian descent and are typically diagnosed... -
New Treatment Approved for Patients with Extensive Stage SCLC
On May 16, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of tarlatamab-dlle (Imdelltra®) to treat patients with extensive-stage small cell lung...